Save

Effects of PeptiSleep in Healthy Males and Females With Mild to Moderate Sleep Impairment

RECRUITING

Examining the effects of PeptiSleep, a plant-based sleep aid, in healthy males and females with mild to moderate sleep impairment.

Simpliy with AI

Study details:

The primary aim of this is a first in human study is to evaluate safety and establish the effective dose in males and females who experience mild to moderate sleep impairment, but who are otherwise healthy. PeptiSleep will be supplemented one hour before bed as a single oral dose of either 250mg, 500mg or 1000mg/day. A placebo group will also be included who will receive 500mg of microcrystalline cellulose.

This trial incorporates a sleep tracking element to measure sleep quality and quantity via a ring which will be worn by participants for the duration of the study. The trial will be conducted over 10 weeks, which includes a 2 week run-in period to gather baseline sleep data, followed by 8 weeks of PeptiSleep supplementation and sleep tracking. The primary endpoint will measure safety and tolerability via adverse event reporting and incidence rate ratio between placebo and PeptiSleep from baseline to the end of the study period.

Secondary endpoints investigated during the trial will include changes sleep quantity and quality, insomnia severity, daytime sleepiness, stress and anxiety, alertness, and biochemistry markers (melatonin, serotonin, CRP, TNFα, IL-6, E/LFT). Exploratory endpoints will include various sleep metrics measured via the wearable tracker including heart rate variability, sleep efficiency, respiratory rate, blood oxygen sensing and daily readiness score.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Males and females 18-65 years

Generally healthy

BMI 18.5 - 33.0.kg/m2

Volunteers who score 0-14 on the ISI screening questionnaire (to exclude insomniacs)

Those with an average sleep score of 89 or less as determined by the sleep tracker during the 14-day run-in period

Must be willing to wear the sleep tracker for the duration of their enrolment

Able to provide informed consent

Agree not to change current diet and/or exercise frequency or intensity during entire enrolment period

Agree not to use other medicines or supplements for sleep, stress, depression, or anxiety other than the test product during enrolment period

Agree to not participate in another clinical trial during enrolment period

Exclusion criteria

Those diagnosed with a chronic sleep disorder, insomnia, restless leg syndrome, sleep apnoea or score of 15 or more on ISI questionnaire

Those with an average sleep score of 90 or over as determined by the sleep tracker during the 14-day run-in period

Those deemed unsuitable based on data from the sleep tracker measurements collected during the 14-day run in period i.e., those with non-wear time exceeding a 24-hour period on more than one occasion

Those using medications which induce CYP3A4 such as phenobarbital, phenytoin, rifampicin, St. John's Wort, and glucocorticoids.

Those using prescription or OTC medications or supplements for sleep, stress, depression or anxiety including CBD within 1 month prior to enrolment.

Those using aromatherapy to help manage sleep, stress, depression, or anxiety within 1 month prior to enrolment.

Use of a digital device (besides the supplied sleep tracker) to help monitor or manage sleep during the study period.

Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years

Serious illness1 e.g., mood disorders such as depression, anxiety or bipolar disorder, neurological disorders such as MS, kidney disease, liver disease or heart conditions

Unstable illness2 e.g., diabetes and thyroid gland dysfunction

Diagnosed or consistent gastrointestinal issues that disrupt sleep.

History of renal function impairment

Volunteers with COPD or a chronic breathing disorder

Currently taking Coumadin (Warfarin), Heparin, Dalteparin, Enoxaparin or other anticoagulation therapy including low dose aspirin

Active smokers, nicotine use or drug (prescription or illegal substances) abuse

Chronic past and/or current alcohol use (>14 alcoholic drinks week)

Regularly taking stimulants (e.g., coffee, caffeine supplements, beverages containing caffeine) 5 hours before bed

Regularly consuming more than 500mg of caffeine per day

Those working night-shift employment who are unable to have a normal night's sleep.

Disturbed sleeping pattern caused by external factors (e.g., young children, partner etc.)

Pregnant or lactating women

Allergic, sensitive, or intolerant to any of the ingredients in active or placebo formula

Participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month and any other sleep clinical trial during the past 3 months.

Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion.

Simplify with AI

Eligibility

Age eligible for study : 18 and older

Healthy volunteers accepted : Yes

Gender eligible for study: All

Things to know

Study dates

Study start: 2024-04-08

Primary completion: 2024-12-30

Study completion finish: 2025-02-20

Study type

OTHER

Phase

Trial ID

NCT06267586

Intervention or treatment

DIETARY_SUPPLEMENT: PeptiSleep

DIETARY_SUPPLEMENT: Placebo MCC micro-crystalline cellulose

Conditions

• Sleep

Condition: Sleep
DIETARY_SUPPLEMENT: PeptiSleep and other drugs
Brisbane, Fortitude Valley Queensland, Australia
Sponsor: Nuritas Ltd

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

RDC Clinical

Research sites nearby

Select from list below to view details:

RDC Clinical
Brisbane, Fortitude Valley Queensland, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: PeptiSleep 250 mg/day Low dose Given as 1 capsule 1 hour before bed	DIETARY_SUPPLEMENT: PeptiSleep Plant protein hydrolysate
EXPERIMENTAL: PeptiSleep 500 mg/day Middle dose Given as 2 capsules 1 hour before bed	DIETARY_SUPPLEMENT: PeptiSleep Plant protein hydrolysate
EXPERIMENTAL: PeptiSleep 1000 mg/day High dose Given as 4 capsules 1 hour before bed	DIETARY_SUPPLEMENT: PeptiSleep Plant protein hydrolysate
PLACEBO_COMPARATOR: Microcrystalline Cellulose 500mg/day Placebo Given as 2 capsules 1 hour before bed	DIETARY_SUPPLEMENT: Placebo MCC micro-crystalline cellulose Placebo MCC micro-crystalline cellulose

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Safety and Tolerability of a dose range of PeptiSleep via adverse event reporting	Change from baseline to the end of the study period in safety via adverse event reporting and incident rate ratio between placebo and a dose range of PeptiSleep	Day 0 to 56

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Safety via electrolytes and liver function tests	Change from baseline to the end of the study period in safety including electrolytes and liver function markers via blood test	Day 0 to 56
Sleep Quality via Leeds Sleep Evaluation Questionnaire	Change from baseline to the end of the study period in Sleep Quality via Leeds Sleep Evaluation Questionnaire (LSEQ). The LSEQ comprises ten self-rating 100-mm-line analogue questions concerned with aspects of sleep and early morning behaviour. A visual analogue scale is used with two extreme states defined at the ends of the line (e. g. Tired = score of 0, Alert = score of 10). The subject responds by placing a vertical mark on the line to indicate his present self- evaluation. The four subscales are as follows: * The ease of getting to sleep (GTS), questions 1-3 * The perceived quality of sleep (QOS), questions 4-5 * The easy of awakening from sleep (AFS), questions 6-7 * The integrity of behaviour following wakefulness (BFW), questions, 8-10	Day 0 to 56
Insomnia severity via the Insomnia Severity Index Questionnaire	Change from baseline to the end of the study period in Insomnia Severity via Insomnia Severity Index (ISI). The questionnaire has seven questions. The seven answers are added up to get a total score. Total score categories: * 0-7 = No clinically significant insomnia * 8-14 = Subthreshold insomnia * 15-21 = Clinical insomnia (moderate severity) * 22-28 = Clinical insomnia (severe)	Day 0 to 56
Sleep onset time via self-reported recording in a Sleep Diary	Change from baseline to the end of the study period in Sleep Onset Time via Consensus Sleep Diary (CSD)	Day 0 to 56
Sleep pattern via self-reported recording in a Sleep Diary	Change from baseline to the end of the study period in self reported Sleeping Pattern and number of Disturbance as recorded using a Consensus Sleep Diary (CSD)	Day 0 to 56
Daytime Sleepiness via the Epworth Sleepiness Scale	Change from baseline to the end of the study period in Day Time Sleepiness and Nap Count via the Epworth Sleepiness Scale (ESS). The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher the propensity for daytime sleepiness * Scores 0-5 Lower Normal Daytime Sleepiness * Scores 6-10 Higher Normal Daytime Sleepiness * Scores 11-12 Mild Excessive Daytime Sleepiness * Scores 13-15 Moderate Excessive Daytime Sleepiness * Scores 16-24 Severe Excessive Daytime Sleepiness.	Day 0 to 56
Stress via the Perceived Stress Scale	Change from baseline to the end of the study period in Stress via a self reported questionnaire - Perceived Stress Scale (PSS). The questions in this scale ask about feelings and thoughts during the last month. The questionnaire asks the participant to indicate how often they felt or thought a certain way with 0 meaning never and 4 meaning very often. PSS scores are calculated by: * First, reverse your scores for questions 4, 5, 7, and 8. On these 4 questions, change the scores like this: 0 = 4, 1 = 3, 2 = 2, 3 = 1, 4 = 0. * Add up your scores for each item to get a total. * Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress. * Scores ranging from 0-13 would be considered low stress. * Scores ranging from 14-26 would be considered moderate stress. * Scores ranging from 27-40 would be considered high perceived stress	Day 0 to 56
Stress via self reported Profile of Mood States Questionnaire	Change from baseline to the end of the study period in Stress via a self reported questionnaire called Profile of Mood States (POMS). The questionnaire contains 65 words that describe feelings which are rated from 0-4. Scores are calculated: * Tension = Tense, Shaky, On Edge, Panicky, Relaxed, Uneasy, Restless, Nervous and Anxious * Depression = Unhappy, Sorry for Things Done, Sad, Blue, Hopeless, Unworthy, Discouraged, Lonely, Miserable, Gloomy, Desperate, Helpless, Worthless, Terrified and Guilty * Anger = Anger, Peeved, Grouchy, Spiteful, Annoyed, Resentful, Bitter, Ready to Fight, Rebellious, Deceived, Furious and Bad Tempered * Fatigue = Worn Out, Listless, Fatigued, Exhausted, Sluggish, Weary and Bushed * Confusion= Confused, Unable to Concentrate, Muddled, Bewildered, Efficient, Forgetful, and Uncertain About Things * Vigour =Lively, Active, Energetic, Cheerful, Alert, Full of Pep, Carefree and Vigorous	Day 0 to 56
Anxiety via self-reported Beck Anxiety Inventory questionnaire	Change from baseline to the end of the study period in Anxiety via Beck Anxiety Inventory (BAI) questionnaire. The BAI consists of 21 self-reported items on a four-point scale - ''not at all'' (0) to ''severely'' (3) to assess the intensity of physical and cognitive anxiety symptoms during the past week. Scores may range from 0 to 63 * Minimal anxiety levels (0-7) * Mild anxiety (8-15) * Moderate anxiety (16-25) * Severe anxiety (26-63)	Day 0 to 56
Stress via Salivary cortisol test	Change from baseline to the end of the study period in Stress via Salivary cortisol test	Day 0 to 56
Alertness via Reaction Time Test	Change from baseline to the end of the study period in Alertness via Reaction Time Test	Day 0 to 56
Circadian cycles via melatonin and serotonin via blood test	Change from baseline to the end of the study period in markers associated with circadian cycles - melatonin and serotonin via blood test	Day 0 to 56
Markers associated with inflammation via blood test	Change from baseline to the end of the study period in Inflammatory Markers such as CRP, TNF-α and IL-6 via blood test	Day 0 to 56
Sleep onset latency via wearable sleep tracker	Change from baseline to the end of the study sleep onset latency measured in minutes using a wearable sleep tracker	Day 0 to 56
Total sleep time spent in sleep phases via wearable sleep tracker	Change from baseline to the end of the study in total sleep time during phases of light, deep and REM sleep measured in minutes via a wearable sleep tracker	Day 0 to 56
Blood pressure via blood pressure machine	Change from baseline to the end of the study in blood pressure measured in mmHG	Day 0 to 56
Heart rate via blood pressure machine	Change from baseline to the end of the study in heart rate measured in beats per minute using a blood pressure machine	Day 0 to 56
Body Temperature via wearable sleep tracker	Change from baseline to the end of the study in body temperature measured in Celsius using a wearable sleep tracker	Day 0 to 56
BMI via height and weight measurements	Change from baseline to the end of the study in BMI. The BMI is calculated by dividing weight in kilograms by height in meters squared and is measured in kg/m2.	Day 0 to 56

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: Effects of PeptiSleep in Healthy Males and Females With Mild to Moderate Sleep Impairment